Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
AR F877L + AR T878A
Cancer:
Prostate Cancer
Drug:
Xtandi (enzalutamide)
(
Androgen receptor inhibitor
)
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Source:
Mol Cancer Ther
Title:
The Effect of F877L and T878A Mutations on Androgen Receptor Response to Enzalutamide
Excerpt:
Our data show that enzalutamide is only a very weak partial agonist of the AR F877L, and a strong partial agonist of the double-mutant AR.
DOI:
10.1158/1535-7163.MCT-15-0892
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login